Vendor Update

IBA and Proton Partners International sign three new ProteusONE contracts

By News Release

IBA (Ion Beam Applications S.A., EURONEXT), a provider of proton therapy solutions for the treatment of cancer, has signed three new contracts with Proton Partners International (PPI), to install three ProteusONE* compact proton therapy solutions across the UK. The contracts are subject to financing.
The contracted ProteusONE solutions include Pencil Beam Scanning (PBS) and Cone-Beam CT (CBCT) capabilities making ProteusONE the only compact solution ready for adaptive treatment, according to a company press release. The contracts also include a maintenance agreement.

The typical end-user price for a ProteusONE solution with a maintenance contract is between EUR 35 and 40 million.

These new centers will be the seventh, eighth and ninth that IBA will install for PPI. IBA has now sold 50 proton therapy centers worldwide, and among them, 21 ProteusONE compact single-room solutions.

Olivier Legrain, Chief Executive Officer of IBA, commented: “We have just completed the installation of the first PT center in the UK in only nine months at the Rutherford Cancer Centre in Newport, South Wales. Today, we are delighted to expand our partnership with PPI, the institution that leads proton therapy penetration in the UK. IBA has the most attractive proton therapy offering and the most affordable solution in the market. IBA has now sold 50 centers across the world and that knowledge and experience is unique in the market. Our competitive strengths will ensure our continued strong position in the market.”
Mike Moran, Chief Executive Officer of Proton Partners International Limited, added: “Just over two and a half years ago, we signed the first agreement with IBA and today we are only a couple of weeks away from treating our first patients at our Rutherford Cancer Centre in Newport, South Wales. IBA has done an excellent job facilitating its installation as well as staff training to speed up patient access to this innovative cancer treatment. The relationship with IBA has been so fruitful and impressive that it was an obvious choice to partner again with them for the expansion of our Rutherford Cancer Centres. Moreover, with ProteusONE, we benefit from the best proton therapy solution on the market.”
“These new contracts support our strategy to build a strong state of the art cancer centre network across the UK to ensure that every cancer patient in the UK can get access to the best possible care without needing to travel far.”
 * ProteusONE is the brand name of Proteus235.